TG Therapeutics, Inc. – LSE:0VGI.L
TG Therapeutics stock price today
TG Therapeutics stock price monthly change
TG Therapeutics stock price quarterly change
TG Therapeutics stock price yearly change
TG Therapeutics key metrics
Market Cap | 5.01B |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | 0.28 |
Revenue | 289.33M |
EBITDA | 49.21M |
Income | 41.19M |
Revenue Q/Q | 713.45% |
Revenue Y/Y | 3275.73% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | 17.01% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeTG Therapeutics stock price history
TG Therapeutics stock forecast
TG Therapeutics financial statements
| Jun 2023 | 16.07M | -47.61M | -296.19% |
|---|---|---|---|
| Sep 2023 | 165.81M | 113.93M | 68.71% |
| Dec 2023 | 43.97M | -14.41M | -32.79% |
| Mar 2024 | 63.47M | -10.70M | -16.87% |
| Dec 2023 | 43.97M | -14.41M | -32.79% |
|---|---|---|---|
| Mar 2024 | 63.47M | -10.70M | -16.87% |
| Sep 2025 | 136.8M | 43.86M | 32.06% |
| Dec 2025 | 158M | 57.02M | 36.09% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 220854000 | 180.40M | 81.68% |
|---|---|---|---|
| Sep 2023 | 331067000 | 166.29M | 50.23% |
| Dec 2023 | 329587000 | 169.08M | 51.3% |
| Mar 2024 | 373323000 | 213.21M | 57.11% |
| Jun 2023 | -42.00M | 30.50M | 47.04M |
|---|---|---|---|
| Sep 2023 | 83.70M | -30.22M | 421K |
| Dec 2023 | -13.21M | -44.75M | -1K |
| Mar 2024 | -8.20M | -9.25M | 10K |
TG Therapeutics alternative data
| Aug 2023 | 237 |
|---|---|
| Sep 2023 | 244 |
| Oct 2023 | 244 |
| Nov 2023 | 244 |
| Dec 2023 | 245 |
| Jan 2024 | 245 |
| Feb 2024 | 245 |
| Mar 2024 | 264 |
| Apr 2024 | 264 |
| May 2024 | 264 |
| Jun 2024 | 284 |
| Jul 2024 | 284 |
TG Therapeutics other data
| Patent |
|---|
Application Filling date: 12 Nov 2021 Issue date: 12 May 2022 |
Application COMBINATION OF ANTI-CD20 ANTIBODY, P13 KINASE-DELTA SELECTIVE INHIBITOR, AND BTK INHIBITOR TO TREAT B-CELL PROLIFERATIVE DISORDERS Filling date: 12 Feb 2021 Issue date: 10 Jun 2021 |
Grant Utility: Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat b-cell proliferative disorders Filling date: 26 May 2017 Issue date: 6 Apr 2021 |
Application Filling date: 29 Jun 2020 Issue date: 15 Oct 2020 |
Grant Filling date: 28 Jun 2017 Issue date: 4 Aug 2020 |
Application COMBINATION OF AN ANTI-CD20 ANTIBODY, PI3 KINASE-DELTA INHIBITOR, AND ANTI-PD-1 OR ANTI-PD-L1 ANTIBODY FOR TREATING HEMATOLOGICAL CANCERS Filling date: 8 Sep 2017 Issue date: 15 Aug 2019 |
| Insider | Compensation |
|---|---|
Mr. Michael S. Weiss (1966) Chief Executive Officer & Pres | $827,540 |
Mr. Sean A. Power CPA, CPA (1982) Chief Financial Officer, Corporation Sec. & Treasurer | $470,560 |
Jenna Bosco Vice President of Investor Relations & Senior Vice President of Corporation Communications | |
Dr. Owen A. O'Connor Chief Scientific Officer | |
Mr. Adam Waldman Chief Commercial Officer |
-
What's the price of TG Therapeutics stock today?
One share of TG Therapeutics stock can currently be purchased for approximately $20.12.
-
When is TG Therapeutics's next earnings date?
Unfortunately, TG Therapeutics's (0VGI.L) next earnings date is currently unknown.
-
Does TG Therapeutics pay dividends?
No, TG Therapeutics does not pay dividends.
-
How much money does TG Therapeutics make?
TG Therapeutics has a market capitalization of 5.01B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 8290.02% to 233.66M US dollars.
-
What is TG Therapeutics's stock symbol?
TG Therapeutics, Inc. is traded on the LSE under the ticker symbol "0VGI.L".
-
What is TG Therapeutics's primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of TG Therapeutics?
Shares of TG Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are TG Therapeutics's key executives?
TG Therapeutics's management team includes the following people:
- Mr. Michael S. Weiss Chief Executive Officer & Pres(age: 59, pay: $827,540)
- Mr. Sean A. Power CPA, CPA Chief Financial Officer, Corporation Sec. & Treasurer(age: 43, pay: $470,560)
- Jenna Bosco Vice President of Investor Relations & Senior Vice President of Corporation Communications
- Dr. Owen A. O'Connor Chief Scientific Officer
- Mr. Adam Waldman Chief Commercial Officer
-
How many employees does TG Therapeutics have?
As Jul 2024, TG Therapeutics employs 284 workers, which is 8% more then previous quarter.
-
When TG Therapeutics went public?
TG Therapeutics, Inc. is publicly traded company for more then 6 years since IPO on 23 Nov 2018.
-
What is TG Therapeutics's official website?
The official website for TG Therapeutics is tgtherapeutics.com.
-
Where are TG Therapeutics's headquarters?
TG Therapeutics is headquartered at 2 Gansevoort Street, New York, NY.
-
How can i contact TG Therapeutics?
TG Therapeutics's mailing address is 2 Gansevoort Street, New York, NY and company can be reached via phone at +212 5544484.
TG Therapeutics company profile:
TG Therapeutics, Inc.
tgtherapeutics.comLSE
319
Medical - Pharmaceuticals
Healthcare
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
New York, NY 10014
:
ISIN: US88322Q1085
:
